Myriad Genetics receives expanded coverage in Japan for breast cancer diagnostic system

Aug. 25, 2022 4:50 PM ETMyriad Genetics, Inc. (MYGN)By: Dania Nadeem, SA News Editor
  • Myriad Genetics (NASDAQ:MYGN) said on Thursday that Japan’s Ministry of Health, Labour and Welfare (MHLW) had granted expanded coverage for the use of its BRACAnalysis Diagnostic System to identify patients with a type of high-risk recurrent breast cancer who may benefit from Lynparza.
  • The company's BRACAnalysis Diagnostic System will be used as a companion diagnostic to identify patients with germline BRCA-mutated (gBRCAm) and HER2-negative high-risk recurrent breast cancer.
  • BRACAnalysis Diagnostic System is designed to detect and interpret germline BRCA1 and BRCA2 variants.
  • Lynparza is jointly developed and commercialized by AstraZeneca (AZN) and MSD.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.